These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7867196)

  • 21. Thrombolytic agents in development.
    Verstraete M; Lijnen HR; Collen D
    Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. A kinetic analysis.
    Bergum PW; Gardell SJ
    J Biol Chem; 1992 Sep; 267(25):17726-31. PubMed ID: 1387641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA; Huang TC; Keyt BA; Alevriadou BR
    Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats.
    Witt W; Baldus B; Bringmann P; Cashion L; Donner P; Schleuning WD
    Blood; 1992 Mar; 79(5):1213-7. PubMed ID: 1536947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Craft TJ; Sundboom JL; Grinnell BW; Bobbitt JL; Burck PJ; Quay JF; Smith GF
    Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
    Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF
    Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
    Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity.
    Schleuning WD; Alagon A; Boidol W; Bringmann P; Petri T; Krätzschmar J; Haendler B; Langer G; Baldus B; Witt W
    Ann N Y Acad Sci; 1992 Dec; 667():395-403. PubMed ID: 1309059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
    Gardell SJ
    Toxicol Pathol; 1993; 21(2):190-8. PubMed ID: 8210941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator.
    Gardell SJ; Duong LT; Diehl RE; York JD; Hare TR; Register RB; Jacobs JW; Dixon RA; Friedman PA
    J Biol Chem; 1989 Oct; 264(30):17947-52. PubMed ID: 2509450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural features mediating fibrin selectivity of vampire bat plasminogen activators.
    Bringmann P; Gruber D; Liese A; Toschi L; Krätzchmar J; Schleuning WD; Donner P
    J Biol Chem; 1995 Oct; 270(43):25596-603. PubMed ID: 7592732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
    Mino T; Suzuki J; Hayashi H
    Jpn J Pharmacol; 1989 Aug; 50(4):429-33. PubMed ID: 2476578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.